CYP — Cynata Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$4.02m
- AU$3.12m
- AU$0.08m
Brief: Cynata Therapeutics Enters Consultancy Agreement With LIR Bio Advisory
Brief: Cynata Therapeutics Establishes Share Sale Facility For Unmarketable Parcel Holders
Brief: Cynata Therapeutics Terminates Of At-The-Market Subscription Deed
Brief: Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million
Brief: Cynata Therapeutics Makes All Employee Positions Redundant Including CEO And MD
Brief: Cynata Therapeutics Seeks Trading Halt
Brief: Cynata Therapeutics Receives Commitments For A$1.5 Mln Placement At A$0.25 Per Share
Australia's Cynata Therapeutics leaps as clinical trial progresses
Brief: Cynata Therapeutics Enters At-Market Subscription Agreement With Acuity Capital
Brief: Cynata Therapeutics Says Cyp-001S FDA Approval Pathway Not Impeded
Brief: Cynata Therapeutics Secures Commitments For A$8.1M Institutional Placement
Brief: Cynata Therapeutics Seeks Trading Halt
Brief: Cynata Therapeutics Ltd Says Co To Acquire Cyp-006Tk Wound Dressing Technology From Tekcyte
Australia's Cynata Therapeutics rises on regulatory approval in EU
Brief: Cynata Therapeutics Gets EU Regulatory & Ethics Approval For Phase 2 Trial In Graft Versus Host Disease
Brief: Cynata Therapeutics Posts HY Loss From Ordinary Activities After Tax Attributable A$4.5 Mln
Australia's Cynata Therapeutics up on starting analysis for wound dressing product
Brief: Cynata Therapeutics Posts FY Net Loss Attributable Of A$14.3 Million
Brief: Cynata Therapeutics Appoints Kilian Kelly As Chief Executive Officer And Managing Director